T Sakari Jokiranta Selected Research

Dientamoebiasis

7/2019

Dientamoeba fragilis - the most common intestinal protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

T Sakari Jokiranta Research Topics

Disease

13	Atypical Hemolytic Uremic Syndrome 01/2021 - 03/2006
6	Infections 01/2022 - 09/2003
5	Macular Degeneration (Age-Related Maculopathy) 01/2017 - 09/2006
2	Lyme Disease (Disease, Lyme) 03/2021 - 06/2013
2	Inflammation (Inflammations) 01/2018 - 03/2007
2	Thrombotic Microangiopathies 10/2012 - 06/2009
2	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 09/2007 - 09/2006
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2021
1	Neuromyelitis Optica (Devic's Disease) 01/2021
1	Giardiasis 07/2019
1	Dientamoebiasis 07/2019
1	Hemolysis 01/2019
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2018
1	Tonsillitis 10/2018
1	Atherosclerosis 01/2018
1	Neoplasms (Cancer) 01/2017
1	Convalescence 01/2017
1	Rheumatoid Arthritis 01/2016
1	Paraproteinemias (Monoclonal Gammopathy) 06/2015
1	Systemic Scleroderma (Systemic Sclerosis) 01/2015
1	Thrombosis (Thrombus) 01/2014
1	Gonorrhea 06/2011
1	Whooping Cough (Pertussis) 01/2011
1	Babesiosis (Piroplasmosis) 07/2010
1	Proteinuria 09/2007
1	Hereditary Complement Deficiency Diseases 09/2007
1	Rare Diseases (Rare Disease) 09/2007
1	Blindness (Hysterical Blindness) 09/2006
1	Urinary Bladder Neoplasms (Bladder Cancer) 05/2005
1	Vaccinia 04/2003
1	Intestinal Volvulus (Volvulus) 06/2002

Drug/Important Bio-Agent (IBA)

16	Complement System Proteins (Complement)IBA 01/2021 - 06/2002
14	Complement Factor H (Factor H)IBA 01/2021 - 05/2005
8	AutoantibodiesIBA 01/2021 - 10/2012
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2003
3	EpitopesIBA 01/2017 - 04/2015
2	Biological ProductsIBA 01/2022 - 01/2016
2	Pharmaceutical PreparationsIBA 08/2021 - 01/2016
2	Peptides (Polypeptides)IBA 01/2017 - 11/2011
2	LigandsIBA 01/2017 - 05/2005
1	vedolizumabIBA 08/2021
1	N 30IBA 03/2021
1	Aquaporin 4IBA 01/2021
1	Aquaporins (Water Channels)IBA 01/2021
1	Formaldehyde (Formol)FDA Link 07/2019
1	Neuraminidase (Sialidase)IBA 01/2019
1	HLA-C Antigens (HLA-C)IBA 10/2018
1	Biomarkers (Surrogate Marker)IBA 10/2018
1	HLA-B57 antigenIBA 10/2018
1	ApolipoproteinsIBA 01/2018
1	Apolipoproteins E (ApoE)IBA 01/2018
1	Amino Acids FDA Link 01/2017
1	AntibodiesIBA 01/2016
1	Infliximab (Remicade)FDA Link 01/2016
1	Adalimumab (Humira)FDA Link 01/2016
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2016
1	Complement C3 Nephritic FactorIBA 06/2015
1	factor H-related protein 1IBA 04/2015
1	Malondialdehyde (Propanedial)IBA 02/2014
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 11/2011
1	LipidsIBA 11/2011
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2011
1	GlycosaminoglycansIBA 02/2011
1	Complement C4b-Binding ProteinIBA 01/2011
1	eculizumab FDA Link 09/2007
1	glucuronyl glucosamine glycan sulfate (sulodexide)IBA 09/2007
1	Rituximab (Mabthera)FDA Link 09/2007
1	Dichlorodiphenyldichloroethane (DDD)IBA 09/2007
1	Retinaldehyde (Retinal)IBA 03/2007
1	C-Reactive ProteinIBA 03/2007
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 03/2007
1	Tumor Biomarkers (Tumor Markers)IBA 05/2005
1	Monoclonal AntibodiesIBA 05/2005
1	VaccinesIBA 09/2003
1	Complement C3b (C3bi)IBA 06/2002

Therapy/Procedure

1	Tonsillectomy 10/2018
1	Transplantation 01/2017
1	Splenectomy 07/2010